Pancreatic Cancer Research

ResearcherAsan Medical CenterActive in the last 2 years

Min Kyu Sung

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9810-7364; OpenAlex author ID A5019047035, A5053818799. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2021: 2 papers · 2022: none · 2023: none · 2024: 4 papers · 2025: 3 papers

Papers 9

  1. Impact of prognostic nutritional index on survival in periampullary/pancreatic cancer patients undergoing pylorus-preserving pancreaticoduodenectomy: A propens… First author DOI 10.1016/j.hbpd.2025.06.007↗
  2. Applicability of current nodal staging system for resected pancreatic cancer after neoadjuvant therapy: a retrospective study. Co-author DOI 10.1016/j.hpb.2025.04.011↗
  3. Oncological outcomes of palliative minimally invasive distal pancreatectomy for unexpected metastatic pancreatic ductal adenocarcinoma: A single-center experie… Co-author DOI 10.1016/j.surg.2025.109331↗
  4. Computed tomography-based vascular burden index as a predictor of vascular resection and pathological vascular invasion in pancreatic cancer with neo-adjuvant … Co-author DOI 10.1016/j.ejso.2024.108494↗
  5. Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000001389↗
  6. Prognostic model for resected borderline and locally advanced pancreatic cancer after neoadjuvant chemotherapy. Co-author DOI 10.1097/js9.0000000000001927↗
  7. Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma. First author DOI 10.4143/crt.2023.977↗
  8. Comparison of Characteristics and Survival Rates of Resectable Pancreatic Ductal Adenocarcinoma according to Tumor Location. Co-author DOI 10.3390/biomedicines9111706↗
  9. Preoperative serum carbohydrate antigen 19-9 levels predict early recurrence after the resection of early-stage pancreatic ductal adenocarcinoma. Co-author DOI 10.4240/wjgs.v13.i11.1423↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ki Byung Song · 8 shared papers, 2021–2025 · strength 1.50
  2. Yejong Park · 8 shared papers, 2021–2025 · strength 1.50
  3. Dae Wook Hwang · 8 shared papers, 2021–2025 · strength 1.50
  4. Song Cheol Kim · 7 shared papers, 2021–2025 · strength 1.31
  5. Woohyung Lee · 7 shared papers, 2021–2025 · strength 1.27
  6. Eunsung Jun · 5 shared papers, 2021–2025 · strength 0.88
  7. Bong Jun Kwak · 3 shared papers, 2021–2024 · strength 0.49
  8. Kyu‐pyo Kim · 2 shared papers, 2024 · strength 0.36
  9. Baek‐Yeol Ryoo · 2 shared papers, 2024 · strength 0.36
  10. Changhoon Yoo · 2 shared papers, 2024 · strength 0.36
  11. Sung-Moon Jeong · 1 shared paper, 2025 · strength 0.28
  12. Yeon-Ju Kim · 1 shared paper, 2025 · strength 0.28
  13. Ji‐Hoon Sim · 1 shared paper, 2025 · strength 0.28
  14. Woohyung Lee · 1 shared paper, 2025 · strength 0.24
  15. Mirang Lee · 1 shared paper, 2025 · strength 0.24
  16. Jimin Son · 1 shared paper, 2024 · strength 0.20
  17. Song Cheol Kim · 1 shared paper, 2024 · strength 0.20
  18. Seung‐Mo Hong · 1 shared paper, 2024 · strength 0.20
  19. Hyoung Jung Kim · 1 shared paper, 2024 · strength 0.20
  20. Yoo Na Lee · 1 shared paper, 2024 · strength 0.19
  21. Inkeun Park · 1 shared paper, 2024 · strength 0.17
  22. Dakyum Shin · 1 shared paper, 2021 · strength 0.11
  23. Sarang Hong · 1 shared paper, 2021 · strength 0.11
  24. Jaewoo Kwon · 1 shared paper, 2021 · strength 0.11
  25. Naru Kim · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.